ImmunoGen, Inc.
IMGNNASDAQHealthcare
$31.24
+$0.01(+0.02%)
Market Cap$8.7B
P/E Ratio—
52W High$31.25
52W Low$3.61
ImmunoGen, Inc. (IMGN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMGN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.11B | $0.07B | $0.13B | $0.08B | $0.05B |
| Cost of Revenue | $0.00B | $0.00B | $0.11B | $0.11B | $0.17B |
| Gross Profit | $0.11B | $0.07B | $0.02B | ($0.03B) | ($0.12B) |
| Gross Margin %(computed) | 99.84% | 100.00% | 13.38% | -39.20% | -223.11% |
| Operating Expenses | |||||
| R&D Expenses | $0.21B | $0.15B | $0.11B | $0.11B | $0.17B |
| G&A Expenses | $0.00B | $0.04B | $0.04B | $0.04B | $0.04B |
| Total Operating Expenses | $0.33B | $0.19B | $0.15B | $0.15B | $0.21B |
| Operating Income | ($0.22B) | ($0.13B) | ($0.14B) | ($0.09B) | ($0.16B) |
| Operating Margin %(computed) | -203.06% | -179.04% | -102.41% | -112.04% | -298.20% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.02B | $0.02B | $0.01B |
| Income Before Tax | ($0.22B) | ($0.14B) | ($0.04B) | ($0.10B) | ($0.17B) |
| Income Tax Expense | $0.00B | $0.00B | $0.02B | $0.02B | $0.00B |
| Net Income | ($0.22B) | ($0.14B) | ($0.07B) | ($0.12B) | ($0.17B) |
| Net Margin %(computed) | -204.93% | -199.41% | -50.40% | -148.40% | -311.94% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.88 | $-1.08 | $-0.38 | $-0.82 | $-1.20 |
| Wtd Avg Shares | 0.25B | 0.21B | 0.18B | 0.15B | 0.14B |
| EBITDA | ($0.22B) | ($0.12B) | ($0.02B) | ($0.07B) | ($0.15B) |
| EBITDA Margin %(computed) | -198.34% | -177.78% | -14.88% | -79.89% | -285.15% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more ImmunoGen, Inc. data
About ImmunoGen, Inc. (IMGN) Income Statement
ImmunoGen, Inc. (IMGN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, IMGN reported revenue of $0.11B, gross profit of $0.11B (gross margin 99.84%), and net income of ($0.22B) — a net profit margin of -204.93%.
Frequently asked questions
IMGN · 4 questionsImmunoGen, Inc. (IMGN) reported revenue of $0.11B for 2022, up 55.7% year-over-year.
IMGN revenueIMGN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09